The cooperation will evaluate the ability of the Lex System to improve therapeutic profiles through optimization of antibody glycosylation structures.
Jan Turek, President and CEO of Biolex, said: “We are pleased to work with Merck Serono, a leader in biologics, to investigate the potential benefits that can be achieved by linking their novel antibody candidate with the glycosylation optimization capabilities of the Lex System.”